title: [A randomized phase I/II trial to compare weekly usage with triple weekly usage of paclitaxel in concurrent radiochemotherapy for patients with locally advanced non-small cell lung cancer].
abstract: OBJECTIVE
  Although the guidelines of the National Comprehensive Cancer Network of USA recommend that the standard therapy for locally advanced non-small cell lung cancer (LANSCLC) is concurrent chemoradiotherapy. There is ongoing controversy about the treatment regimen which combines chemotherapy concurrently with radiotherapy. The aim of this study is to compare weekly usage with triple weekly usage of paclitaxel in concurrent radiochemotherapy for patients with LANSCLC, and to obtain the best paclitaxel regimen in the concurrent radiochemotherapy.
  
  
  METHODS
  From April 2006 to April 2009, some LANSCLC patients in multicenter were randomly divided into weekly usage (45 mg/m², 1 times/week, a total of 270 mg/m² in six weeks) and triple weekly usage (15 mg/m², 3 times/week, a total of 270 mg/m² in six weeks) group of paclitaxel by a random number table. All patients were treated with 3D radiotherapy, and 95% planning target volume (PTV) received a prescription dose of (60-70) Gy/(30-35)times/(6-7)weeks, (1.8-2.0) Gy/fraction. Then the side effects, response and overall survival rate were compared between two groups of patients.
  
  
  RESULTS
  Thirty-eight LANSCLC patients were enrolled. Weekly usage and triple weekly usage group were 20 and 18 patients, respectively. In the triple weekly usage group, the side effects were 12 patients had radiation esophagitis of I-II degree, 1 patient had radiation esophagitis of III degree, 2 patients had radiation pneumonitis of I degree, 1 patient had radiation pneumonitis of II degree, 1 patient had radiation pneumonitis of III degree and died of respiratory failure, 2 patients developed weight loss of I degree. In the weekly usage group, the side effects were 11 patients had radiation esophagitis of I-III degree, 6 patients had radiation pneumonitis of II-III degree, 2 patients developed weight loss of I degree, 6 patients developed leucopenia of III-IV degree. The response rate of two groups was 88.8% and 50.0%, respectively (P=0.026). 1-year survival rate of two groups was 79% and 67%, respectively (P=0.607).
  
  
  CONCLUSIONS
  Although the preliminary results did not show the merits of survival in triple weekly usage, but preliminary results show that triple weekly usage was more safe and effective than weekly usage of paclitaxel in concurrent radiochemotherapy for patients with LANSCLC.
authors.affiliation: Department of Radiation Oncology, Beijing Cancer Hospital and Institute, Peking University School of Oncology, Beijing, China.
authors.forename: Anhui
authors.initials: A
authors.lastname: Shi
authors.forename: Guangying
authors.initials: G
authors.lastname: Zhu
authors.forename: Rong
authors.initials: R
authors.lastname: Yu
authors.forename: Yingjie
authors.initials: Y
authors.lastname: Wang
authors.forename: Tingyi
authors.initials: T
authors.lastname: Xia
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000532:radiotherapy*; D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage*; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents; D017239:Paclitaxel